Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 822.

https://doi.org/10.1182/blood-2024-208902

Published: 2024

Journal Articles

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Alexandros Rampotas, Zoe Wong, Isaac Gannon, Camelia Benlabiod, Yuqi Shen, Charlotte Brierley, Aude-Anais Olijnik, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, Marina Mitsikakou, Manuel Rodriguez-Justo, Abdullah O Khan, Adam J Mead, Jonathan Lambert, Claire Roddie, Bethan Psaila, Martin A Pule

Blood (2024) 144 (Supplement 1): 871.

https://doi.org/10.1182/blood-2024-204953

Published: 2024

Journal Articles

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Adam J Mead, Brian J P Huntly, Bethan Psaila, Claire Harrison, Rebecca Boucher, Jiayi Wang, Rebecca Collings, Zsofia Nagy, Rebecca Record

Blood (2024) 144 (Supplement 1): 3186.

https://doi.org/10.1182/blood-2024-205105

Published: 2024

Journal Articles

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Blood (2024) 144 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2024-204818

Published: 2024

Journal Articles

Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms - All Clones Are Not Equal

Onima Chowdhury, Kristian Gurashi, Amy Wood, Ivan Lukic, Adam Sciambi, Lynn Quek, Daniel H Wiseman, Adam J Mead

Blood (2024) 144 (Supplement 1): 3615.

https://doi.org/10.1182/blood-2024-210047

Published: 2024

Journal Articles

Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Antonio Rodriguez-Romera, Rong Li, Nah-Young Shin, Sally-Ann Clark, Assunta Adamo, Affaf Aliouat, Abdullah Khan, Aude-Anais Olijnik, Jill Brown, Lucia Sommerova, Natalie Jooss, Akiko Shimamura, Xin Lu, Guanlin Wang, Stefan N. Constantinescu, Ketan Patel, Adam J Mead, Alan B. Cantor, Bethan Psaila

Blood (2024) 144 (Supplement 1): 421.

https://doi.org/10.1182/blood-2024-203123

Published: 2024

Journal Articles

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Blood (2024) 144 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2024-207251

Published: 2024

Journal Articles

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Blood (2024) 144 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2024-207135

Published: 2024

Journal Articles

Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis

Blood (2024) 144 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2024-207224

Published: 2024

Journal Articles

Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Rosalin Cooper, Emily Thomas, Dawood Muhammad, Carlo Pescia, Anna Sozanska, Oliver McCallion, Hosuk Ryou, Renuka Teague, Alan King Lun Liu, Joanna Hester, Fadi Issa, Bethan Psaila, Adam J Mead, Jens Rittscher, Dan Woodcock, Daniel Royston

Blood (2024) 144 (Supplement 1): 876.

https://doi.org/10.1182/blood-2024-205266

Published: 2024

Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Blood (2024) 144 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2024-194031

Published: 2024

Journal Articles

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Blood (2024) 143 (2): 178–182.

https://doi.org/10.1182/blood.2023022345

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells

Sahoko Matsuoka, Raffaella Facchini, Tiago C. Luis, Joana Carrelha, Petter S. Woll, Takuo Mizukami, Bishan Wu, Hanane Boukarabila, Mario Buono, Ruggiero Norfo, Fumio Arai, Toshio Suda, Adam J. Mead, Claus Nerlov, Sten Eirik W. Jacobsen

Blood (2023) 142 (19): 1622–1632.

https://doi.org/10.1182/blood.2022019018

Published: 2023

Includes: Supplemental data

Journal Articles

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

Blood (2023) 142 (Supplement 1): 993.

https://doi.org/10.1182/blood-2023-178556

Published: 2023

Journal Articles

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Jennifer O Sullivan, Amy Wood, Sean Wen, Angela Hamblin, Sonia Fox, Christina Yap, Mary Frances McMullin, Nicholas C. P. Cross, Claire N Harrison, Adam J Mead

Blood (2023) 142 (Supplement 1): 4552.

https://doi.org/10.1182/blood-2023-185043

Published: 2023

Journal Articles

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Jennifer O Sullivan, Sean Wen, Affaf Aliouat, Alba Rodriguez-Meira, Sally-Ann Clark, Neil Ashley, Amy Wood, Ramy Slama, Guanlin Wang, Angela Hamblin, Lauren Murphy, Christina Simoglou Karali, Charlotte K Brierley, Adam P Cribbs, Aimee Paterson, Claire N Harrison, Bethan Psaila, Adam J Mead

Blood (2023) 142 (Supplement 1): 861.

https://doi.org/10.1182/blood-2023-185118

Published: 2023

Journal Articles

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Sean Wen, Jennifer O Sullivan, Joanna Baxter, Nikolaos Sousos, Adam J Mead, Alba Rodriguez-Meira

Blood (2023) 142 (Supplement 1): 4133.

https://doi.org/10.1182/blood-2023-185999

Published: 2023

Journal Articles

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Adam J Mead, Claire N Harrison, Brian Huntly, Bethan Psaila, Rebecca Boucher, Sonia Fox, Louise Hopkins, Joseph Rogers, Charlotte Gaskell, Amit Patel

Blood (2023) 142 (Supplement 1): 6442.

https://doi.org/10.1182/blood-2023-185798

Published: 2023

Journal Articles

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Blood (2023) 142 (Supplement 1): 620.

https://doi.org/10.1182/blood-2023-173509

Published: 2023

Journal Articles

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Blood (2023) 142 (Supplement 1): 277.

https://doi.org/10.1182/blood-2023-182697

Published: 2023

NARROW

Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia

Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment

Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study

Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms - All Clones Are Not Equal

Tolerance of Whole Genome Duplication in Megakaryocytes, and Consequences for Their Genome Integrity

Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis

Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Loss of endothelial membrane KIT ligand affects systemic KIT ligand levels but not bone marrow hematopoietic stem cells

Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A

The SF3B1 K666 Hotspot Mutation Confers Unfavourable Disease Risk across Major Myeloid Neoplasm Subgroups

Cooperation between SF3B1 and JAK2 V617F Mutations Accelerates Fibrotic Progression in Myeloproliferative Neoplasms By Enhancing STAT1 Signaling

Single-Cell Mutation Profiling and Alternative Splicing Analysis Reveals Distinct Aberrant Splicing of U2AF1 S34 and U2AF1 Q157 in Myeloid Malignancies

Promise: Investigation into the Combination of a Potent Beti with Ruxolitinib in Patients with High or Intermediate-2 Risk Myelofibrosis Not Receiving an Adequate Response with Ruxolitinib Alone

Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

Platelets Sequester Extracellular DNA, Capturing Tumour-Derived and Free Fetal DNA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only